Literature DB >> 18930997

Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.

T Tucker1, J M Friedman, R E Friedrich, R Wenzel, C Fünsterer, V-F Mautner.   

Abstract

BACKGROUND: Plexiform neurofibromas are benign tumours that occur in more than half of people with neurofibromatosis 1 (NF1). These tumours can cause serious complications and can also progress to malignant peripheral nerve sheath tumours (MPNSTs), one of the leading causes of death among NF1 patients. Plexiform neurofibromas are clinically heterogeneous, and knowledge of their natural history is limited. In order to characterise the growth of plexiform neurofibromas better, we performed serial magnetic resonance imaging (MRI) in NF1 patients with such tumours.
METHODS: MRI was done on 44 plexiform neurofibromas in 34 NF1 patients (median age 10 years; range 1-47 years). Each tumour was measured in two dimensions from the MRI scan, and the area and growth rate were calculated. The median length of follow-up was 6 years, with an average interval of 3 years between scans.
RESULTS: 36 tumours remained stable in size throughout the period of follow-up. 8 tumours increased in size; all occurred in patients who were under 21 years of age when first studied. The single exception was a man who developed rapid tumour growth and pain in a plexiform neurofibroma that had been followed for 10 years. Biopsy showed the presence of an MPNST.
CONCLUSION: Longitudinal MRI is a valuable means of monitoring the growth of plexiform neurofibromas in individuals with NF1.

Entities:  

Mesh:

Year:  2008        PMID: 18930997     DOI: 10.1136/jmg.2008.061051

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  31 in total

1.  Extensive plexiform neurofibroma in a premature neonate.

Authors:  Aditya Joshi; Moira Lancelot; Nandita R Bhattacharjee; Sruthi Polavarapu; Efstathios Beltaos; Babatunde Sobowale
Journal:  Clin Med Res       Date:  2014-11-07

2.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander Vinks; Alan Cantor; John Perentesis; Elizabeth Schorry; Nicole Ullrich; David H Gutmann; James Tonsgard; David Viskochil; Bruce Korf; Roger J Packer; Michael J Fisher
Journal:  Neuro Oncol       Date:  2014-10-14       Impact factor: 12.300

3.  Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits.

Authors:  Ivayla Apostolova; Dagmara Niedzielska; Thorsten Derlin; Eva J Koziolek; Holger Amthauer; Benedikt Salmen; Jens Pahnke; Winfried Brenner; Victor F Mautner; Ralph Buchert
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-18       Impact factor: 6.200

4.  Plexiform neurofibroma causing an ossifying subperiosteal haematoma: a rare case in the tibia of an 11-year-old girl.

Authors:  Anton Lavell; Christopher W Jones; Daniel Wong; Peter Counsel; Richard Carey-Smith
Journal:  Skeletal Radiol       Date:  2017-06-16       Impact factor: 2.199

5.  Interactive segmentation of plexiform neurofibroma tissue: method and preliminary performance evaluation.

Authors:  Lior Weizman; Lior Hoch; Dafna Ben Bashat; Leo Joskowicz; Li-tal Pratt; Shlomi Constantini; Liat Ben Sira
Journal:  Med Biol Eng Comput       Date:  2012-06-16       Impact factor: 2.602

6.  Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.

Authors:  Urania Dagalakis; Maya Lodish; Eva Dombi; Ninet Sinaii; Jessica Sabo; Andrea Baldwin; Seth M Steinberg; Constantine A Stratakis; Brigitte C Widemann
Journal:  J Pediatr       Date:  2013-12-08       Impact factor: 4.406

7.  Surgery for Peripheral Nerve Sheath Tumours of the Buttocks, Legs and Feet in 90 Patients With Neurofibromatosis Type 1.

Authors:  Reinhard E Friedrich; Caglayan T Tuzcu
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 8.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

9.  Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.

Authors:  Maria Demestre; Jan Herzberg; Nikola Holtkamp; Christian Hagel; David Reuss; Reinhard E Friedrich; Lan Kluwe; Andreas Von Deimling; Victor-F Mautner; Andreas Kurtz
Journal:  J Neurooncol       Date:  2009-11-17       Impact factor: 4.130

10.  Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions.

Authors:  Srivandana Akshintala; Andrea Baldwin; David J Liewehr; Anne Goodwin; Jaishri O Blakeley; Andrea M Gross; Seth M Steinberg; Eva Dombi; Brigitte C Widemann
Journal:  Neuro Oncol       Date:  2020-09-29       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.